This study concluded that basal tumours with KRT5/6, p63, and KRT14 expression had a better response to chemotherapy, while luminal tumours with active PPAR expression and activating mutations in FGFR3 showed expression of KRT20, FOXA1, and GATA3. This evidence concerns the gene KRT5 and neoplasm.